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Accepted 7 March 2016Background: Although most low-dose combined oral contraceptives (COCs) include 7-day hormone-free
intervals (HFIs), these COCs could incompletely suppress ovarian activity. Objectives: To review the impact of
HFIs on ovarian suppression and tolerability, and evaluate the utility of COCs without traditional 7-day HFIs.
Search strategy: PubMed was searched for clinical studies published in English between January 1980 and April
2015 on the impact of HFIs and HFI modiﬁcations in COCs. Selection criteria: Articles assessing contraceptive
efﬁcacy or tolerability as the primary focus were included. Data collection and analysis: Abstracts of 319 articles
were screened. Results: Analysis of the 161 articles selected revealed that suppression of ovarian activity with
low-dose COCs with 7-day HFIs is suboptimal. Loss of ovarian suppression during 7-day HFIs is commonly
associated with follicular development, and most dominant follicles appear during this period. By contrast, in-
creased ovarian suppression was noted in regimens that shortened or eliminated the HFI, or that substituted
low-dose ethinyl estradiol for the HFI. Conclusions: Extended regimens with modiﬁed HFIs may provide greater
ovarian suppressionwith the potential for increased contraceptive effectiveness. Additional research is needed to
evaluate whether COC regimens that include 10 μg ethinyl estradiol instead of an HFI may improve tolerability.
© 2016 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. All rights reserved.Keywords:
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When combined oral contraceptives (COCs) were introduced more
thanﬁve decades ago, the 21/7 regimen (21 days of active pills, followed
by a 7-day hormone-free interval [HFI]) was chosen in an effort to
mimic women's monthly menstrual cycles and to reassure women
that they were not pregnant [1,2]. Although reﬁnements such as
new progestogens, reduced doses of ethinyl estradiol (EE), the use of
estradiol, and reduction or elimination of the HFI have been introduced
in combined hormonal contraception, most COC users continue to take
active pills for 21 days followed by a 7-day HFI. Evidence suggests,
however, that 21/7 regimens might not completely suppress ovarian
activity and ovarian development.
The primary aim of the present review was therefore to evaluate
evidence regarding the potential impact of the 7-day HFI on ovarian
activity, contraceptive effectiveness, and adverse effects. The impact of
COC options with shorter HFIs or less frequently occurring HFIs as
compared with traditional 21/7 regimens was also considered.A, Suite 100, Lutherville, MD
0.
y and Obstetrics. Published by Elsevi2. Materials and methods
In a structured review, PubMed was searched to identify studies on
the impact of HFIs and modiﬁcations in HFIs in COCs that were pub-
lished in English between January 1, 1980, and January 15, 2015. The
last search datewas April 30, 2015. The keywords usedwere “combined
hormonal contraceptive,” “oral contraceptive,” “hormone-free interval,”
“ovarian suppression,” “extended regimen,” “ethinyl estradiol,” and
“hormone withdrawal.” Articles were excluded if they did not evaluate
the impact of HFIs on ovarian activity, contraceptive effectiveness, or
adverse effects; or they did not consider regimens with modiﬁed HFIs.
Reference lists of included studies were manually searched to identify
additional papers.3. Results
3.1. Search results
The abstracts of 319 articles were screened, and 161 articles
underwent full-text review. The complete list of articles included in
the analysis is provided in Supplementary Material S1.er Ireland Ltd. All rights reserved.
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COCs provide contraception by inhibiting the hypothalamic–
pituitary–ovarian (HPO) axis, suppressing follicular growth, and
inhibiting ovulation [3,4]. The primary role of the progestogen
component of COCs is to prevent ovulation through a negative feedback
mechanism that results in a decrease in luteinizing hormone (LH) [4].
Progestogen action also reduces the receptivity of cervicalmucus and de-
creases endometrial thickness [4]. Estrogens contribute to the contracep-
tive mechanism of COCs by inhibiting both follicle-stimulating hormone
(FSH) and LH. The inhibition of FSH seems to be related to estrogen dose
and duration, because more follicular activity is seen with progestogen-
only methods than with COCS, and with regimens with lower EE doses
(b35 μg) than with those with higher EE doses [5,6]. Most COCs do not
completely suppress ovarian follicular development [7,8].
A possible explanation for the incomplete ovarian suppression seen
with today's COCs is the clearance of contraceptive steroid hormones
during the HFI. In fact, evidence indicates that the hormonal events
and follicular growth that take place during the HFI are similar to
those seen early during the follicular phase of spontaneous menstrual
cycles [7]. In the normal menstrual cycle, selection of the dominant fol-
licle occurs within the ﬁrst 7 days [1]. These physiologically selected
dominant follicles secrete estradiol, which stimulates their maturation
and inhibits the growth of subordinate follicles [8]. Dominant follicles
(usually ≥10 mm) have the greatest potential to develop further and
ovulate [9]. Among women using COCs, a loss of endocrine suppression
during the HFI is associated with follicular development [1,6,8,10].
Indeed, evidence suggests that 86% of dominant follicles emerge during
the 7-day HFI, irrespective of the regimen [8]. Womenwho initiate COC
use after 7 days of follicle growth could already have a dominant follicle
that can continue to develop and possibly ovulate [11].
Modern COCs may also provide incomplete ovarian suppression
owing to their reduced estrogen dose. Early COCs contained estrogen
doses as high as 150 μg. Although the lower EE doses in today's COCs
(generally ≤35 μg) have improved safety and tolerability, accumulating
evidence suggests that the decreasing EE doses could have compro-
mised the degree to which COCs suppress HPO activity, particularly
during the HFI [1,8].
Although the half-life of EE is constant irrespective of dose, its
maximum concentration is related to dose and, because EE is cleared
from the system 2–3 days after the ﬁnal active pill, the threshold level
at which recovery of the HPO axis and follicular growth can occur is
achieved earlier with very low-dose EE pills [3,7]. It could take as long
as 12 days to achieve steady-state estrogen and progestogen levels
among obese women using COCs with a 7-day HFI [12], and follicular
development could continue into the ﬁrst week of the next cycle.
In a recent pilot study, Cho et al. [13] evaluated the impact of various
21/7 regimens during the 7-day HFI and found better suppression of
pituitary and ovarian activity with 30- and 35-μg EE formulations on
day 1 of the HFI as compared with regimens that included 20 μg EE.
Mean levels of LH, FSH, and estradiol increased during the HFI in all
regimens; at day 7, however, LH and FSH levels were similar among
the groups. Maximum estradiol levels at day 7 were 477, 247, and
199 pg/mL for the 20-, 30-, and 35-μg EE doses, respectively [13].
Follicular development is also greater among women using COC
regimens with 20 μg EE than among those using regimens with higher
EE doses [3,6]. The reduced ovarian suppression observed with lower
EE doses and long HFIs might be particularly relevant in clinical situa-
tions when a missed pill occurs early in the cycle following the HFI
[1,12,14]. It is not uncommon to miss pills during the ﬁrst week of the
COC cycle. In one study [15], 23% of women using COCs reportedmissing
a pill at least once during a 28-day cycle, and 42% of womenwhomissed
a pill did so during the ﬁrst week of the cycle following the HFI.
The pharmacokinetics of COCs in obese women could differ from
those in women of normal weight, which could lead to inadequate
ovarian suppression and potentially to escape ovulation [14]. Thesepharmacokinetic differences are magniﬁed in obese women using
COCs with lower-dose EE formulations. Given the rapid increase in the
prevalence of obesity, these differences in pharmacokinetics and their
possible impact on ovarian suppression may have important implica-
tions for the effectiveness of COCs in the general population, although
the true impact of weight versus non-compliance on oral contraceptive
efﬁcacy is debated [16].
Strategies to mitigate the impact of decreasing EE doses on ovarian
suppressionhavebeen evaluated. In a recent study, Edelmanet al. [12] ex-
amined the impact of two strategies that might counteract the effect of
obesity on COC pharmacokinetics: elimination of the HFI or use of a
higher-dose levonorgestrel (LNG)/EE regimen cyclically. In their study,
obesewomen (bodymass index [calculated asweight in kilograms divid-
ed by the square of height in meters] ≥30) used a 21/7-day LNG/EE
(100 μg/20 μg) regimen (Aviane, Teva Pharmaceuticals, Petah Tikva,
Israel) for two cycles and were then randomized to continuous LNG/EE
(100 μg/20 μg) with no HFI or to higher-dose cyclic 21/7 LNG/EE
(150 μg/30 μg; Portia, Barr Laboratories, Pomona, NY, USA). During the
baseline cycle, the average time to reach the steady-state plasma LNG
concentrationwas 12.3 days, and 45% ofwomenhad evidence of follicular
activity [12]. After randomization, both continuous LNG/EE (100 μg/
20 μg) and cyclic LNG/EE (150 μg/30 μg) reduced follicular activity as
compared with the standard 21/7 LNG/EE (100 μg/20 μg) regimen.
Only 9% of women in each group showed evidence of follicular activity
[12]. Although the time to reach a steady LNG concentration was de-
layed for women using the higher-dose pill, the threshold level
needed to inhibit the HPO axis was achieved earlier. Women using
the lower-dose pill remained continuously at the steady-state level of
plasma LNG.
These data indicate that ovarian suppression can be incomplete in
regimens that include a 7-day HFI, particularly when very low estrogen
doses are used. Incomplete ovarian suppression might have several
important consequences, including an increase in follicular develop-
ment, a heightened risk of escape ovulation, a potential reduction in
contraceptive effectiveness, a potential increase in the risk of unsched-
uled bleeding, and an increase in the incidence and severity of
hormone-withdrawal symptoms [1].
For example, Sulak et al. [2,17] have demonstrated that the adverse
effects—e.g. headache, pelvic pain, bloating, breast tenderness, and use
of pain medication—are signiﬁcantly more frequent and more severe
during the HFI than during the period of active COC use. These symp-
toms tend to increase during the last week of active pills and continue
to increase during the HFI—a pattern that parallels the decrease in
endogenous estrogen levels during the same period [18]. Therefore,
modifying the HFI has the potential to reduce the frequency and severity
of hormone-withdrawal symptoms related to COC use. Continuous dos-
ing without an HFI has been found to reduce symptoms related to the
menstrual cycle in users of a low-dose LNG/EE (100 μg/20 μg) pill [19].
Because ovarian activity and inadequate ovarian suppression
occurring during the 7-day HFI have been associated with an increased
risk of unscheduled bleeding in the following cycle [1], it is thought that
increased ovarian suppression might reduce the risk of unscheduled
bleeding and improve cycle control [20].
3.3. Alternatives to the traditional HFI
The limitations of the 7-day HFI—including inadequate ovarian sup-
pression and the potential for hormone-withdrawal symptoms—reinforce
the importance of alternative approaches to traditional COC regimens.
One option to improve ovarian suppression and reduce the
incidence of hormone-withdrawal symptoms is to use extended or
continuous regimens, which reduce the number of HFIs. In extended
regimens, active COC pills are administered for longer than 28 days
and the time between HFIs is extended. A frequently used extended
regimen is the 84/7 regimen (84 active days, followed by 7 days of no
treatment; Seasonale, Teva Women's Health, Sellersville, PA, USA) or
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Pharmaceutical Products, Horsham, PA, USA). In continuous regimens,
active COC pills are taken continuously without an HFI for at least 1 year.
Flexible regimens that enablewomen to choosewhen to have a short-
ened HFI have also been introduced in some countries [21]. Several for-
mulations use a 24/4 regimen, such as drospirenone/EE (Yasmin or Yaz;
Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA), norethindrone/
EE (e.g. Minastrin 24; Actavis Pharma, Parsippany, NJ, USA), and
nomegestrol acetate/estradiol (Zoely, Teva B.V., Haarleem, Netherlands);
and one uses a 26/2 regimen (dienogest/estradiol valerate; Natazia,
Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA).
Both shortening the HFI and reducing the frequency of HFIs have
signiﬁcant advantages. As discussed above, an important advantage of
regimens with modiﬁed HFIs is that they provide greater suppression
of pituitary–ovarian activity as compared with traditional 21/7
regimens. Observational evidence from a large prospective cohort of
more than 52 000 women suggests that the greater suppression of
ovarian activity achieved with regimens that have shorter HFIs
could translate into reduced rates of pregnancy [22]. Similar results
were found in a retrospective analysis of a claims database by How-
ard et al. [23], who evaluated extended regimens. Rates of pregnancy
were signiﬁcantly lower for 84/7 regimens than for 21/7 regimens
(4.4% vs 7.3%; P b 0.001) or 24/4 regimens (4.4% vs 6.9%; P b 0.001)
[23]. In a follow-up analysis, Howard et al. [24] also reported that extend-
ed regimens were associated with fewer pregnancy complications and
pregnancy-related costs.
An obvious and intended effect of reducing the number of HFIs is a
reduction in the number of scheduled bleeding episodes. Monthly
withdrawal bleeds and their associated symptoms are associated with
signiﬁcant personal, economic, social, and societal costs [25]. A reduced
number of scheduled withdrawal bleeds might result in decreased
use of female hygiene products and over-the-counter pain relievers, ab-
senteeism, lost wages, and reduced productivity owing tomenstruation-
related symptoms [25]. However, women using an 84/7 regimen might
spend slightly more on pregnancy tests and possibly physician
visits owing to unscheduled bleeding. Economic analyses of the cost-
effectiveness of cyclic versus extended (84/7) regimens found that
extended regimens are associated with signiﬁcant cost savings if both
regimens are equivalently priced [25].
Shortening theHFI also has an important effect on cycle control. Reg-
imens with shorter HFIs are associated with shorter lighter scheduled
bleeding episodes and fewer unscheduled bleeding episodes [26,27]. A
reduction in the frequency and duration of the HFI will also probably
decrease the frequency and possibly decrease the severity of symptoms
related to hormone withdrawal. Indeed, a recent Cochrane analysis
concluded that extended and/or continuous regimens were associated
with a reduced frequency and severity of hormonewithdrawal symptoms
as compared with standard cyclic regimens [28].
An alternative to shortening or eliminating the HFI is to add a low
dose of EE (e.g. 10 μg) during the HFI to suppress ovarian follicular
developmentwhile permittingmonthly bleeding [1].Whereas recent sys-
tematic and narrative reviews have evaluated the impact of a shortened
HFI and extended regimens on contraceptive effectiveness and tolerabili-
ty [28,29], the impact of using low-dose EE (10 μg) during the traditional
HFI has received less attention in the clinical literature.
Supplementing the HFI with low-dose estrogen could ultimately
improve suppression of HPO activity by inhibiting FSH [3,11]. Several
studies of cyclic 28-day COCs have evaluated the impact of substituting
low-dose EE during the HFI on HPO activity [1,7,30–32]. For example,
greater ovarian suppression has been observed among women who
received 21 days of desogestrel/EE, 2 days of placebo, and 5 days of
10 μg EE (Mircette; Organon, West Orange, NJ, USA) as compared with
those who received a 28-day regimen with a 7-day pill-free interval
(Alesse; Wyeth-Ayerst Pharmaceuticals, Philadelphia, PA, USA) [30,31].
Women who received the Mircette regimen had fewer and smaller per-
sistent follicles as comparedwithwomen assigned to a 7-dayHFI [30,31].Another study compared the impact of two 21/7 LNG/EE (150 μg/
30 μg) COC regimens: one with a 7-day placebo-based HFI, and one
with supplementation of 10 μg of EE for 7 days [7]. Endocrine data dem-
onstrated that 10 μg of EE taken during the traditional HFI was linked to
greater suppression of ovarian function as compared with a traditional
HFI. The large increases in FSH, estradiol, and inhibin B with placebo
during the HFI were similar to those seen in a normal menstrual cycle,
suggesting the development of ovarian follicles.
A more recent study compared the ovulatory effects of three differ-
ent 28-day COCs: an investigational COC regimen including 21 days
of desogestrel/EE (150 μg/20 μg), followed by 7 days of 10 μg of EE
(desogestrel/EE + EE); 24 days of drospirenone/EE (3 mg/20 μg),
followed by placebo for 4 days (drospirenone/EE + placebo; Yaz);
and 21 days of LNG/EE (100 μg/20 μg), followed by placebo for 7 days
(LNG/EE + placebo; Lessina, Teva Pharmaceuticals, North Wales, PA,
USA) [32]. Although similar suppression of ovarian function and inhibi-
tion of ovulationwere seen in all regimens, EE supplementation delayed
the increase in estradiol concentrations following the HFI.
By extending the interval between HFIs and reducing the number
of HFIs, extended regimens are expected to provide greater ovarian
suppression than 21/7 COCs. Whether adding 10 μg EE during the
7-dayHFIwhenusing extended regimens provides even greater ovarian
suppression should also be evaluated.
Vandever et al. [1] compared follicular activity among women
assigned to one of three different regimens: an extended 84/7 LNG/EE
(150 μg/30 μg) regimen with low-dose EE supplementation during the
HFI (84/7 EE, Seasonique), an extended 84/7 LNG/EE (150 μg/30 μg)
regimen with a traditional HFI (Seasonale), and a 21/7 regimen with a
traditional HFI (Portia). Assessments of FSH revealed signiﬁcant sup-
pression in the 84/7 EE group as compared with the groups receiving
the traditional 7-day HFI [1]. Fig. 1 depicts changes in FSH, LH, and EE
levels before, during, and after the traditional HFI with each regimen.
The FSH suppression observedwith 84/7 EE correlated with a reduction
in the number of developing follicles [1]. A phase I study of 84/7 EE has
conﬁrmed these ﬁndings [33].
Few studies have compared the impact of low-dose EE supplemen-
tation during the traditional HFI on contraceptive failure rates. In an
analysis of insurance claims [34], pregnancy rates among women
using 84/7 regimens with EE supplementation were signiﬁcantly
lower than were pregnancy rates among women using 84/7 regimens
with a traditional HFI (3.0% vs 4.5% in year 1; P b 0.001). Women
using 84/7 EE regimens had a higher medication possession ratio (an
indicator of adherence), which researchers attributed to amore favorable
bleeding proﬁle as compared with the 84/7 placebo regimen.
Although extended regimens increase ovarian suppression and re-
duce the number of withdrawal bleeds as compared with traditional
21/7 regimens [35], they are associated with an increased incidence of
unscheduled breakthrough bleeding—an adverse effect that could
prompt early discontinuation of COC [36]. It has been hypothesized
that adding low-dose EE during the HFI in extended regimens could
further inhibit ovarian activity and consequently reduce the risk of
unscheduled bleeding [36].
The effects of EE supplementation on the incidence of unscheduled
bleeding occurring during extended regimens have not been speciﬁcally
evaluated in a head-to-head trial. In a cross-study analysis, however,
Kaunitz et al. [36] evaluated the impact of two different 91-day COC
regimens—one with a 7-day HFI (Seasonale) and the other with 7 days
of 10 μg EE (Seasonique)—on bleeding and spotting. This analysis dem-
onstrated that there was less scheduled bleeding with the EE regimen
thanwith the placebo-based HFI during days 85–91, with signiﬁcant dif-
ferences noted at each 91-day cycle [36]. Additionally, unscheduled
bleeding decreased more rapidly with the regimen containing low-
dose EE instead of placebo. These data suggest that the use of low-dose
estrogen could improve bleeding proﬁles and cycle control.
Several studies have demonstrated that low-dose EE supplementa-
tion during the traditional HFI provides a signiﬁcant improvement in
Fig. 1. Changes in (A) FSH, (B) LH, and (C) estradiol levels before, during, and after a
traditional or modiﬁed HFI. Asterisks indicate a signiﬁcant difference between 84/7 EE
and 21/7 regimens (P b 0.05) [1]. The indicated day of US examination is the point in
which patients using 84/7 EE had a reduced number of follicles compared with the same
point within their control cycle, while patients using 21/7 or 84/7 regimens did not
differ (P N 0.56). Abbreviations: FSH, follicle-stimulating hormone; LH, luteinizing
hormone; EE, ethinyl estradiol; SE, standard error; US, ultrasonography; OC, oral
contraceptive; HFI, hormone-free interval. Reproduced from Vandever et al. [1], with
permission from Elsevier.
11A. London, J.T. Jensen / International Journal of Gynecology and Obstetrics 134 (2016) 8–12ovarian suppression; however, its impact on symptoms of hormone
withdrawal is less clear. Previous studies have not been powered to de-
tect differences in hormone-withdrawal symptoms in comparative
studies of COC regimens supplemented with low-dose EE [1,7],
although preliminary data from Vandever et al.’s [1] study indicated a
trend toward amodest reduction in headache scores during the interval
supplemented by low-dose EE as compared with the traditional HFI. By
contrast, another study that evaluated headache rates with a 21/7 LNG/
EE (150 μg/30 μg) regimenwith andwithout EE supplementation found
no difference in headache rates [7]. Additional research on the impact
of low-dose EE supplementation during the HFI on symptoms of
withdrawal is needed.
Owing to the association between estrogen dose and adverse events,
evaluation of the safety of low-dose EE supplementation during the HFI
is essential. Annual EE exposure for 21/7 regimenswith 10 μg of EE sup-
plementation is comparable to that for 24/4 regimens. Endometrial
safety during cycles in which low-dose EE is used during the traditional
HFI is similar to that reported for conventional regimens [37,38].
Adverse event proﬁles are also generally similar among regimenswith
and without low-dose EE supplementation; however, previous studies
have not beenpowered to look at rare events such as venous thromboem-
bolisms or cardiovascular events. Veriﬁcation of the clinical safety of these
regimens awaits large-scale post-marketing prospective studies similar
in size to the European Active Surveillance and the International Active
Surveillance studies of women taking oral contraceptives [39,40].
4. Discussion
Over the past few decades, numerous changes to COC regimens have
been introduced to improve safety, tolerability, and adherence. However,
there is growing evidence that current COC formulations provide inade-
quate suppression of ovarian activity owing to their low EE doses, partic-
ularly during the traditional HFI when no contraceptive steroids are
administered. Inadequate ovarian suppression, irrespective of which
COC is used, can result in escape ovulation and possibly in unscheduled
bleeding.Women using COCswith traditional HFIs could also experience
adverse effects associated with hormone withdrawal, such as headache,
pelvic pain, bloating, and breast tenderness—symptoms that increase in
parallel with the decrease in endogenous estrogen.
Recent data indicate that increasing ovarian suppression by incorpo-
rating modiﬁcations to the HFI could help to improve COC efﬁcacy,
safety, and tolerability. Extending the number of active pills by reducing
the frequency or the length of the HFI and supplementing traditional
HFIs with low-dose EE are two useful approaches. Both extended
regimens and regimens in which low-dose EE is given during the HFI
could help to decrease the incidence of escape ovulation, contraceptive
failure, unscheduled bleeding, and the incidence and severity of symp-
toms resulting from hormone withdrawal, especially with extended
84/7 regimens. Extended regimens are also associated with fewer epi-
sodes of withdrawal bleeding and cost savings because of a reduced
need for feminine hygiene products and pain relievers, and a lower risk
of reduced productivity due to symptoms related to hormonewithdraw-
al. Existing evidence suggests that the safety proﬁles of extended regi-
mens and regimens that substitute low-dose EE for the HFI are similar
to those of traditional regimens; however, these data need to be veriﬁed
by results from large long-term post-marketing surveillance studies.
Womenwhoare considering COCswith fewerHFIs such as extended
regimens, or COCs with low-dose EE supplementation during the tradi-
tional HFI should be counselled on the practical beneﬁts and potential
risks of these regimens. Approaches that improve the oral contraceptive
experience and enhance outcomes should be a priority for patients,
providers of contraception, and researchers—all of whom are looking to
improve on the great success of oral contraception in women's health.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ijgo.2015.10.028.
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